These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical usefulness of 123I-IMP scintigraphy in the diagnosis of bone metastases from hepatocellular carcinoma: comparison with 99mTc-MDP bone scintigraphy].
    Author: Suto Y, Tanigawa N, Iwamiya T, Kato T, Endo K, Shabana M, Ohta Y.
    Journal: Nihon Igaku Hoshasen Gakkai Zasshi; 1993 Aug 25; 53(8):953-9. PubMed ID: 8396760.
    Abstract:
    The diagnostic value of N-isopropyl-p-[123I]-iodoamphetamine (123I-IMP) scintigraphy was evaluated in 12 patients with 20 bone metastases from hepatocellular carcinoma, in comparison with 99mTc-methylene diphosphonate (99mTc-MDP) bone scintigraphy. Sixteen lesions (80%) were detected by 123I-IMP scintigraphy, whereas four lesions (two lesions in the rib and two lesions after a radiation of 40 Gy) were missed. Of 16 lesions demonstrated as areas of increased uptake in 123I-IMP scan, only eight (50%) showed an increased pattern of uptake in 99mTc-MDP bone scintigraphy. In conclusion, 123I-IMP is a promising radiopharmaceutical for the detection of bone metastases from hepatocellular carcinoma.
    [Abstract] [Full Text] [Related] [New Search]